On August 31, BEONE MEDICINES fell 4.19% at open, trading at HK$215.0, with turnover of HK$5.0095 million. The stock has been under sustained selling pressure following the release of its interim results on August 26.

The company reported H1 revenue of RMB 22.22 billion, up 26.84% year-over-year, and net profit attributable to shareholders of RMB 3.271 billion, surging 627.15% YoY. However, Q2 standalone net profit grew only approximately 3% quarter-over-quarter, and revenue growth has shown a persistent deceleration trend, raising market concerns over the sustainability of high growth. Since the earnings release, the A-share price has dropped 6.07% in one week, with net institutional outflows exceeding RMB 75 million on August 28 alone. Additionally, executive Lay Strong sold approximately US$19.66 million worth of shares on August 12, further dampening market sentiment and reinforcing profit-taking activity among investors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)